Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 14/20 | 0.66 |
| ▸ | DYRK1A | Q13627 | 5/20 | 0.56 |
| ▸ | TTK | P33981 | 1/20 | 0.53 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.53 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.53 |
| ▸ | CLK1 | P49759 | 1/20 | 0.53 |
| ▸ | CLK2 | P49760 | 1/20 | 0.53 |
| ▸ | CLK3 | P49761 | 1/20 | 0.53 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.53 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.53 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.50 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22985867 | 0.95 | LRRK2 (0.73) | LRRK2TTKMAP3K9MKNK2 | |
| SCHEMBL18018792 | 0.88 | LRRK2 (0.65) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018966 | 0.87 | LRRK2 (0.74) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018932 | 0.86 | LRRK2 (0.88) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018960 | 0.86 | LRRK2 (0.68) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL22985899 | 0.86 | LRRK2 (0.76) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018950 | 0.85 | LRRK2 (0.75) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018954 | 0.85 | LRRK2 (0.72) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL22985893 | 0.85 | LRRK2 (0.72) | LRRK2DYRK1ATTKDYRK3CSNK1E | |
| SCHEMBL18018938 | 0.85 | LRRK2 (0.72) | LRRK2DYRK1ATTKDYRK3CSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |